This is an aggregated industry headline. Read the full story at FierceBiotech →
'Greg, you've got to bring back this platform': How LifeMine won over Gates and Bezos for $188M series E
A little over a year ago, LifeMine Therapeutics laid off staff and put its fungus-based platform on ice to focus its dwindling resources on its lead asset. Now, the Massachusetts biotech is shaking off the cobwebs thanks in part to substantial investments from billionaires Bill Gates and Jeff Bezos.
By FierceBiotech
· Aug 6, 2026
· via FierceBiotech
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Despite a major curveball thrown by the FDA earlier this year, Moderna has managed to strike true with a U.S. …
The WeekBriefing
Takeda won FDA approval for Orzeyful in adults with narcolepsy type 1. The decision introduces the first appro…
The WeekSTAT News ↗
Scientist-turned-biotech executive Greg Verdine is having a very good year.…